Schizophrenia Trial, Recruiting (NCT04629352)

Schizophrenia Trial, Recruiting NCT04629352 Sponsor: National Institute of Mental Health and Neuro Sciences, India Condition: Schizophrenia

Printed from Voxsanity (voxsanity.com.au) — NCT04629352 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Schizophrenia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with schizophrenia or schizoaffective disorder, based on standard diagnostic guidelines (DSM-5)
People who experience auditory verbal hallucinations (hearing voices) that are considered clinically significant
People who are right-handed
People who are able and willing to provide written consent to participate

Who may not be able to join:

People who are currently experiencing a psychiatric emergency
People who have any medical reason that would make a type of mild brain stimulation treatment called tDCS unsafe for them (confirm with trial site)
People who are pregnant or have recently given birth
People who are left-handed or use both hands equally

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anushree Bose, PhD, Department of Psychiatry, NIMHANS, Bengaluru, Karnataka, India

Phone: +91-8026995366

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04629352

Sponsor: National Institute of Mental Health and Neuro Sciences, India

Phase: Not Applicable

Status: Recruiting

Condition: Schizophrenia

Trial contact: +91-8026995366

More information: https://clinicaltrials.gov/study/NCT04629352

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with schizophrenia or schizoaffective disorder, based on standard diagnostic guidelines (DSM-5)
People who experience auditory verbal hallucinations (hearing voices) that are considered clinically significant
People who are right-handed
People who are able and willing to provide written consent to participate

Who may not be able to join:

People who are currently experiencing a psychiatric emergency
People who have any medical reason that would make a type of mild brain stimulation treatment called tDCS unsafe for them (confirm with trial site)
People who are pregnant or have recently given birth
People who are left-handed or use both hands equally

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Institute of Mental Health and Neuro Sciences, India

Registry

ClinicalTrials.gov

Start date

2 April 2024

Est. completion

31 August 2026

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Neurophysiological Measure: Change in amplitude of N100-related waveforms; Neuro-Chemical Measure: Change in concentration of glutamate-glutamine levels; Neuro-haemodynamic Measure: Change in strength of resting-state-functional-connectivity among brain areas; Clinical Measure: Change in auditory verbal hallucination score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov